Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1677-1681

  Di Carlo, Angelina ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clear cell renal cell carcinoma; Matrix metalloproteinase 9; MMP 9 lipocalin complex; Neutrophil gelatinase associated lipocalin; Oncocytoma; Serum; Urine

Indexed keywords

GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; ONCOCYTOMA; URINALYSIS;

EID: 84875724601     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1252     Document Type: Article

References (23)

1. Flower DR: The lipocalin protein family: structure and function. Biochem J 318: 1-14, 1996.
2. Di Carlo A: The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res 2: doi: 10.7362/2240-2594.057.2012.
3. Triebel S, Bläser J, Reinke H and Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314: 386-388, 1992.
4. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
5. Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755: 37-69, 2005.
6. Yan L, Borregaard N, Kjeldsen L and Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276: 37258-37265, 2001.
7. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Bertger T, Mak TW, Knebelmann B, Friedlander G, Barasch J and Terzi F: Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 120: 4065-4076, 2010.
8. Chakraborty S, Kaur S, Guha S and Batra SK: The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826: 129-169, 2012.
9. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A and Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52: 595-605, 2008.
10. Cho H and Kim JH: Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 57: 513-521, 2009.
11. Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY, Zhao ZS and Tao HQ: Expression of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and ancillary diagnostic test. Anat Rec (Hoboken) 293: 1855-1863, 2010.
12. Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, FlessasI, Goussetis E, Nonni A, Papassotiriou I and ZografosG: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 9: 390, 2009.
13. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, ShostromVK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, BrandRE, Hollingsworth MA, Jain M and Batra SK: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 98: 1540-1547, 2008.
14. Sobin LH and Wittekind CH (eds): International Union Against Cancer (UICC) TNM Classification Of Malignant Tumors. 6th edition. New York, NY, Wiley-Liss, pp193-195, 2002.
15. Kashyap MK, Kumar A, Emelianenko N, Kashyap A, KaushikR, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK and Upadhyaya SK: Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10: 258-294, 2005.
16. Di Carlo A: Matrix metalloproteinase-2 and-9 in the sera and in the urine of human oncocytoma and renal cell carcinoma. Oncol Rep 28: 1051-1056, 2012.
17. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M and BarresiG: Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: Correlation with histotype and histological grade. Oncol Rep 24: 305-310, 2010.
18. Perrin C, Patard JJ, Jouan F, Collet N, Théoleyre S, EdelineJ, Zerrouki S, Laguerre B, Bellaud-Roturaud MA, Rioux-LeclercqN and Vigneau C: The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal carcinoma. Prog Urol 21: 851-858, 2011 (In French).
19. Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, ImarisioI and Canipari C: Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77: 809-815, 2010.
20. Morrissey JJ, London AN, Lambert MC and Kharasch ED: Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am J Nephrol 34: 391-398, 2011.
21. Fernández CA, Yan L, Louis G, Yang J, Kutok JL and MosesMA: The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11: 5390-5395, 2005.
22. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610-6617, 2008.
23. Smith ER, Zurakowski D, Saad A, Scott RM and Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14: 2378-2386, 2008.